Unlocking the promise of cell & gene therapy
Cambridge, MA
Joined March 2016
- Tweets279
- Following140
- Followers1.4K
- Likes82
Today at 3:40 pm, Jan ter Meulen, M.D., Ph.D., CSO, will present “Armoring TIL for Increased Persistence, Potency and Impact on the Tumor Microenvironment” during the IO360° Summit @ConferenceForum.
Check out the full agenda at theconferenceforum.org/confe…
Jan ter Meulen, M.D., Ph.D., CSO, will present #cytoTIL15 preclinical data during the #poster presentation “Armoring tumor infiltrating lymphocytes (TIL) with regulatable, membrane bound IL15 for increased persistence and potency, without the use of concomitant IL2”.
Our partnership with @VertexPharma was featured in @nature as one of the top 20 strategic alliance deals in the #celltherapy and #genetherapy space. The collaboration leverages our cytoDRiVE technology to discover controllable genetic therapies. Read more: bit.ly/3FgkAqQ
.@FierceBiotech covered our partnership extension with @bmsnews. The collaboration extension provides the exclusive option for BMS to in-license rights for #celltherapy candidates utilizing our #cytoDRiVE technology to control the expression of CD40L. bit.ly/3DQrqT2
#SITC22 – Our team will be presenting the poster “Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15™ therapy) in an allogeneic melanoma PDX model” today.
#CheckItOut: obsidiantx.com/news-releases…
Today our poster “Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models” will be presented by our team at #SITC.
Learn more about all our posters at @sitcancer: obsidiantx.com/news-releases…
Our team will present the poster “Enhancers of innate and adaptive immunity combine with membrane-bound IL15 to increase the efficacy of (TIL) therapy for tumors with immunosuppressive microenvironments” today at @sitcancer. #SITC22
Learn more: bit.ly/3A3zUns
Today we announced that we will be presenting #preclinical data highlighting our recent #cytoDRiVE platform and pipeline advances during the poster sessions at #SITC22 @sitcancer.
For more details on the presentations and abstract summaries: obsidiantx.com/news-releases…
#InvestorConference - Our management team will be attending the @SVBLeerink Biopharma Private Company Connect virtually October 26 –27.
Today we announced the extension of our multi-year strategic collaboration with @BMSnews for the discovery and development of novel, regulated cell therapies that utilize our cytoDRiVE technology!
Read more: obsidiantx.com/news-releases…
#CGT #celltherapy
Our #CSO, Jan Ter Meulen, Ph.D., will be presenting at the TIL Therapies Summit, today at 12:30 PM ET. He will discuss our #TILtherapy candidate #OXB115 in a presentation titled “Engineering an IL2-Free, Potent & Persistent TIL with Regulated Membrane-Bound IL15.”
#IL2 #IL15
Jan ter Meulen, Ph.D., #CSO at Obsidian, will be participating in a panel discussion at the Neoantigen Based Therapies Summit, today at 2 PM ET on strategies to counter the TME.
#IL2 #IL15 #celltherapy #cancer
Obsidian’s Shyam Subramanian, Ph.D., #CTO, will be speaking today at the Process Development for #Cell Therapy Summit at 3:00 pm ET in Woburn, MA.
Learn more: obsidiantx.com/news-releases…
Obsidian’s Director of Process Development, Katie Aron, Ph.D., will be speaking today at the Process Development for #Cell Therapy Summit at 2:30 p.m. ET in Woburn, MA.
Learn more: obsidiantx.com/news-releases…
Our #CEO, Paul Wotton, spoke with @MattPillar of the #BusinessofBiotech #podcast about Obsidian’s path to @FDA clearance of the IND application for #OBX115 this past summer.
Listen @BioProcessOL: bioprocessonline.com/doc/ind…
#Summit – Our #team will be attending the @Jefferies Cell & Genetic Medicine Summit happening in NYC September 29 - 30.
Our management team will also be participating in 1x1 #investormeetings during the event.
Obsidian Therapeutics #CSO, Jan ter Meulen, Ph.D., will be attending @Citi 17th Annual BioPharma Conference 2022 and participating in a panel on #celltherapy on September 7, at 3:30 p.m. ET, Boston.
Learn more: obsidiantx.com/news-releases…
As reported by @Becca_Carballo of @HoustonChron – #OBX115 received IND clearance, and clinical trials in #metastaticmelanoma will begin soon. The research teams hope they have found a technique that is more effective without harsh side effects: bit.ly/3dskmkP
